+25%

est. 2Y upside i

HealthcareSeries B

FidoCure® is the leader in Precision Medicine for Canine Oncology.

Rank

#1527

Sector

Veterinary Oncology, Biotechnology

Est. Liquidity

~5Y

Data Quality

Data: Low

FidoCure has strong upside potential driven by its unique dataset and patent, but missing financial data and high capital intensity create significant uncertainty.

Last updated: July 19, 2026

Bull (20%)+198%

Revenue grows to $13.2M with multiple holding at 18x due to AI patent and large dataset; upside after dilution is 197.7%.

Base (35%)+21%

Revenue grows to $13.2M but multiple converges to 8x (in line with public comps); upside after dilution is 21.2%.

Bear (45%)-49%

Revenue disappoints or competition pressures multiple to 4x; exit value $53M still above preference, but dilution and low multiple lead to -49.3%.

Est. time to liquidity~4.5 years

Preference Stack Risk

severe

Funding Intensity

43%

Total funding of $32.1M against estimated $75M valuation implies 43% preference overhang, severely diluting common stock in downside scenarios.

Dilution Risk

high

With $32.1M total funding and high burn rate, another raise within 24 months is likely, resulting in 15-25% dilution.

Secondary Liquidity

none

No secondary market activity detected; shares are illiquid until a liquidity event.

Questions to Ask at the Interview

Strategic questions based on FidoCure®'s data — designed to show you've done your homework.

  • 1

    “How does FidoCure plan to compete with deep-pocketed incumbents like Zoetis and Elanco?”

  • 2

    “What is the path to profitability given the high burn rate and capital intensity?”

  • 3

    “What is the expected timeline for a liquidity event, and how will common shareholders be treated in an acquisition?”

Community

Valuation Sentiment

Our model estimates +25% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.